Last reviewed · How we verify
NCT02578511
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Phase 1 trial testing Ixazomib in Acute Lymphoblastic Leukemia in Complete Remission. Withdrawn.
13 February 2018
Quick facts
| Lead sponsor | Ehab L Atallah |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 29 June 2017 |
| Primary completion | 13 February 2018 |
| Estimated completion | 13 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ixazomib (IXAZOMIB) — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia in Complete Remission — all drugs for Acute Lymphoblastic Leukemia in Complete Remission →
- Lymphoblastic Lymphoma in Complete Remission — all drugs for Lymphoblastic Lymphoma in Complete Remission →
- Mixed Phenotype Acute Leukemia in Complete Remission — all drugs for Mixed Phenotype Acute Leukemia in Complete Remission →
Sponsor
Ehab L Atallah — full company profile →
Who can join
18 and older, any sex, with Acute Lymphoblastic Leukemia in Complete Remission or Lymphoblastic Lymphoma in Complete Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this phase I study, escalating doses of IXAZOMIB will be combined with the POMP/D regimen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02578511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ixazomib
Trials testing the same drug.
- NCT05722405 — Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma · Phase 4 · recruiting
- NCT05183139 — A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide an · Phase 4 · withdrawn
- NCT04998786 — A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myel · Phase 2 · active not recruiting
- NCT04837131 — A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients · Phase 2 · terminated
- NCT03888534 — Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphob · Phase 1 · withdrawn
Other Ehab L Atallah trials
Trials by the same sponsor.
- NCT05038644 — XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia · Phase 1 · terminated
- NCT03140280 — Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodys · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02578511 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ehab L Atallah
- Last refreshed: 15 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02578511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing